This pharma stock has a massive upside, analyst says
Roth Capital Partners analyst Jonathan Aschoff says Medicus Pharma’s (Medicus Pharma Stock Quote, Chart, News, Analysts, Financials NASDAQ:MDCX) licensing deal with Pfizer shifts the company more directly toward oncology.
In a Sept. 9 update, Aschoff reiterated his “Buy” rating and US$9.00 target on Medicus.
Medicus and Pfizer agreed to co-develop PF-08046031, also known as CD228V, an early-stage antibody-drug conjugate targeting melanotransferrin, or CD228.
CD228V is now Medicus’s lead development asset, with relapsed or refractory melanoma selected as the first indication.
Medicus will lead development and may develop, manufacture and commercialize CD228V for any disease. Pfizer will provide certain development funding and is eligible for milestones and royalties.
Medicus paid Pfizer US$12-million upfront and must pay another US$15-million on the first anniversary of the deal’s effective date. Pfizer paid Medicus US$2-million to support development and will provide about US$8-million to US$10-million of drug inventory, along with development and intellectual property support.
Aschoff said the changes represent a more efficient use of capital and add a differentiated oncology asset to the story.
Medicus also reprioritized its pipeline. SkinJect will now focus on Gorlin syndrome rather than sporadic or nodular basal cell carcinoma. Teverelix will focus on acute urinary retention and symptomatic endometriosis rather than advanced prostate cancer.
Gorlin syndrome could support orphan drug pricing and offers a more favourable competitive environment than sporadic or nodular basal cell carcinoma.
Pfizer has identified high CD228 expression across several tumour types, including melanoma, squamous non-small cell lung cancer, head and neck squamous cell carcinoma and esophageal cancer.
Aschoff said CD228 is also a less crowded target than many cancer antigens pursued by other antibody-drug conjugates.
-30-
Rod Weatherbie
Writer
Rod Weatherbie is a journalist based in Prince Edward Island. Since 2004, he has written extensively about the Canadian property and casualty insurance landscape. He was also a founder and contributing editor for a Toronto-based arts website and a PEI-based food magazine. His fiction and poetry have been featured in The Fiddlehead, The Antigonish Review, and Juniper.

